The causality between Type 2 diabetes and breast cancer: a bidirectional two-sample Mendelian randomization study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J. Clin. 67(6), 439–448 (2017).
  MedlineGoogle Scholar
• 2. Lipscombe LL, Chan WW, Yun L, Austin PC, Anderson GM, Rochon PA. Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 56(3), 476–483 (2013).
  Medline CASGoogle Scholar
• 3. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 33(7), 1674–1685 (2010).
  MedlineGoogle Scholar
• 4. Bordeleau L, Lipscombe L, Lubinski J et al. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117(9), 1812–1818 (2011).
  Medline CASGoogle Scholar
• 5. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA 318(19), 1925–1926 (2017).
  MedlineGoogle Scholar
• 6. Hu M, Li X, Yang Y. Causal associations between cardiovascular risk factors and venous thromboembolism. Semin. Thromb. Hemost. 49(7), 679–687 (2023).
  Medline CASGoogle Scholar
• 7. Hu MJ, Tan JS, Gao XJ, Yang JG, Yang YJ. Effect of cheese intake on cardiovascular diseases and cardiovascular biomarkers. Nutrients 14(14) 1–11 (2022).
  Google Scholar
• 8. Xue A, Wu Y, Zhu Z et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nat. Commun. 9(1), 2941 (2018).
  MedlineGoogle Scholar
• 9. Michailidou K, Lindström S, Dennis J et al. Association analysis identifies 65 new breast cancer risk loci. Nature 551(7678), 92–94 (2017).
  Medline CASGoogle Scholar
• 10. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int. J. Epidemiol. 40(3), 755–764 (2011).
  MedlineGoogle Scholar
• 11. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from Mendelian randomization analyses with multiple genetic variants. Epidemiology 28(1), 30–42 (2017).
  MedlineGoogle Scholar
• 12. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44(2), 512–525 (2015).
  MedlineGoogle Scholar
• 13. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol. 46(6), 1985–1998 (2017).
  MedlineGoogle Scholar
• 14. Hemani G, Zheng J, Elsworth B et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).
  MedlineGoogle Scholar
• 15. Pearson-Stuttard J, Papadimitriou N, Markozannes G et al. Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomization studies. Cancer Epidemiol. Biomarkers Prev. 30(6), 1218–1228 (2021). • Meta-analysis of observational studies suggested that diabetes increased the risk of breast cancer.
  Medline CASGoogle Scholar
• 16. Liu Q, Aggarwal A, Wu M et al. Impact of diabetes on outcomes in breast reconstruction: a systematic review and meta-analysis. J. Plast. Reconstr. Aesthet. Surg. 75(6), 1793–1804 (2022).
  MedlineGoogle Scholar
• 17. Liu YS, Wu PE, Chou WC et al. Body mass index and type 2 diabetes and breast cancer survival: a Mendelian randomization study. Am. J. Cancer Res. 11(8), 3921–3934 (2021).
  MedlineGoogle Scholar
• 18. Escala-Garcia M, Morra A, Canisius S et al. Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BMC Med. 18(1), 327 (2020). • Systematic review of Mendelian randomization studies suggested that diabetes increased the risk of breast cancer.
  Medline CASGoogle Scholar
• 19. Yuan S, Kar S, Carter P et al. Is type 2 diabetes causally associated with cancer risk? Evidence from a two-sample Mendelian randomization study. Diabetes 69(7), 1588–1596 (2020). • Mendelian randomization study suggested that breast cancer increased the risk of diabetes.
  Medline CASGoogle Scholar
• 20. Hwangbo Y, Kang D, Kang M et al. Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol. 4(8), 1099–1105 (2018). •• A large Korean cohort study suggested that cancer development increased the risk of subsequent diabetes.
  MedlineGoogle Scholar
• 21. Au Yeung SL, Schooling CM. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. BMJ Open Diabetes Res. Care 7(1), e000872 (2019).
  MedlineGoogle Scholar
• 22. Mohn A, Di Marzio A, Capanna R, Fioritoni G, Chiarelli F. Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia. Lancet 363(9403), 127–128 (2004).
  Medline CASGoogle Scholar
• 23. Yoshida H, Imamura T, Saito AM et al. Protracted administration of L-asparaginase in maintenance phase is the risk factor for hyperglycemia in older patients with pediatric acute lymphoblastic leukemia. PLOS ONE 10(8), e0136428 (2015).
  MedlineGoogle Scholar
• 24. Meacham LR, Sklar CA, Li S et al. Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch. Intern. Med. 169(15), 1381–1388 (2009).
  MedlineGoogle Scholar
• 25. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75(Suppl. 10), S3–S24 (2003).
  MedlineGoogle Scholar
• 26. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr. Pract. 15(5), 469–474 (2009).
  MedlineGoogle Scholar
• 27. Lipscombe LL, Fischer HD, Yun L et al. Association between tamoxifen treatment and diabetes: a population-based study. Cancer 118(10), 2615–2622 (2012).
  Medline CASGoogle Scholar
• 28. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350, g7607 (2015).
  MedlineGoogle Scholar
• 29. Schoenfeld JD, Ioannidis JP. Is everything we eat associated with cancer? A systematic cookbook review. Am. J. Clin. Nutr. 97(1), 127–134 (2013).
  Medline CASGoogle Scholar
• 30. Boffetta P, McLaughlin JK, La Vecchia C, Tarone RE, Lipworth L, Blot WJ. False-positive results in cancer epidemiology: a plea for epistemological modesty. J. Natl Cancer Inst. 100(14), 988–995 (2008).
  MedlineGoogle Scholar
• 31. Kavvoura FK, Liberopoulos G, Ioannidis JP. Selection in reported epidemiological risks: an empirical assessment. PLOS Med. 4(3), e79 (2007).
  MedlineGoogle Scholar
• 32. Ioannidis JP. The importance of potential studies that have not existed and registration of observational data sets. JAMA 308(6), 575–576 (2012).
  Medline CASGoogle Scholar